Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Schwannoma development is mediated by Hippo pathway dysregulation and modified by RAS/MAPK signaling
Zhiguo Chen, Stephen Li, Juan Mo, Eric Hawley, Yong Wang, Yongzheng He, Jean-Philippe Brosseau, Tracey Shipman, D. Wade Clapp, Thomas J. Carroll, Lu Q. Le
Zhiguo Chen, Stephen Li, Juan Mo, Eric Hawley, Yong Wang, Yongzheng He, Jean-Philippe Brosseau, Tracey Shipman, D. Wade Clapp, Thomas J. Carroll, Lu Q. Le
View: Text | PDF
Research Article Genetics Oncology

Schwannoma development is mediated by Hippo pathway dysregulation and modified by RAS/MAPK signaling

  • Text
  • PDF
Abstract

Schwannomas are tumors of the Schwann cells that cause chronic pain, numbness, and potentially life-threatening impairment of vital organs. Despite the identification of causative genes, including NF2 (Merlin), INI1/SMARCB1, and LZTR1, the exact molecular mechanism of schwannoma development is still poorly understood. Several studies have identified Merlin as a key regulator of the Hippo, MAPK, and PI3K signaling pathways; however, definitive evidence demonstrating the importance of these pathways in schwannoma pathogenesis is absent. Here, we provide direct genetic evidence that dysregulation of the Hippo pathway in the Schwann cell lineage causes development of multiple schwannomas in mice. We found that canonical Hippo signaling through the effectors YAP/TAZ is required for schwannomagenesis and that MAPK signaling modifies schwannoma formation. Furthermore, cotargeting YAP/TAZ transcriptional activity and MAPK signaling demonstrated a synergistic therapeutic effect on schwannomas. Our new model provides a tractable platform to dissect the molecular mechanisms underpinning schwannoma formation and the role of combinatorial targeted therapy in schwannoma treatment.

Authors

Zhiguo Chen, Stephen Li, Juan Mo, Eric Hawley, Yong Wang, Yongzheng He, Jean-Philippe Brosseau, Tracey Shipman, D. Wade Clapp, Thomas J. Carroll, Lu Q. Le

×

Figure 2

Lats1 or Lats2 loss of heterozygosity in H7;Lats1/2mut3 mice is required for schwannoma development.

Options: View larger image (or click on image) Download as PowerPoint

Lats1 or Lats2 loss of heterozygosity in H7;Lats1/2mut3 mice is require...
(A) IHC of LATS1 and LATS2 on schwannoma and sciatic nerve sections from H7;Lats1/2mut3 mice. (B) Diagram of PCR primer design for detecting the WT, Flox, or Δfloxed alleles of Lats1 or Lats2. (C) Gel electrophoresis of DNSC and tumor PCR products. β-Actin was used as an internal control (n = 3–4). Y, Ad-Cre infected; N, no Ad-Cre infected; T, tumors; M, DNA marker. (D) Diagram of experimental design for testing tumor formation potential of E13.5 DNSCs in vivo. (E) Morphology of E13.5 DNSCs (Lats1/2mut) infected with Ad-GFP or Ad-Cre. (F) Left: Gross picture of nude mice injected with E13.5 DNSCs (Lats1/2mut4-Ad-GFP) (left side) or E13.5 DNSCs (Lats1/2mut4-Ad-Cre) (right side, red circles) (n = 4). Right: H&E histology (top) and IHC (bottom) for LATS1 and LATS2 in Lats1/2mut4-Ad-Cre tumor. L1/2mut4, Lats1/2mut4; +Con, positive control; H7, Hoxb7-Cre; L1, Lats1; L2, Lats2. Scale bars: 50 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts